Does antihypertensive treatment chosen based on plasma renin activity (PRA) improve blood pressure control in untreated hypertensive patients?
Selecting antihypertensive monotherapy based on plasma renin activity does not significantly improve overall blood pressure control rates in a general hypertensive population, though it may offer modest benefits in diastolic blood pressure reduction.
BACKGROUND: We investigated the extent of blood pressure (BP) reduction and control (<140/90 mmHg) in patients treated with appropriate or inappropriate drugs according to their plasma renin activity (PRA) level (natriuretic drugs and renin-angiotensin system blockers for low-renin and high-renin hypertension, respectively). PATIENTS AND METHODS: One hundred and seventy Caucasian untreated hypertensive patients (61 females), aged 18-70 years, participated to the study. Patients with secondary hypertension, diabetes or established cardiovascular or renal disease were excluded. The physician prescribed an antihypertensive monotherapy chosen among all drug classes, unaware of patient's PRA levels. We compared effect of an inappropriate or appropriate drug, evaluating BP values after a month of treatment. RESULTS: Rate of BP control was not significantly higher in patients treated with an appropriate drug than the others (38% vs 29%, p=0.24). However, in a regression analysis, final diastolic BP (DBP) was lower in subjects treated with an appropriate drug (beta=-2.84, p=0.03). CONCLUSIONS: The present study does not clearly support the use of PRA in a general population of hypertensive patients to optimize BP control. However, the greater efficacy of a drug appropriate to PRA in reducing DBP may be clinically helpful in young hypertensive patients. Future studies are warranted to evaluate if PRA determination enhances the therapeutic success in patients with predominantly high values of DBP.
Leotta et al. (Tue,) studied this question.